ACTRN12612000915853已完成1 期
A prospective, bilateral, cross-over study to evaluate the safety and subjective acceptance of a novel contact lens multipurpose disinfecting solution and compare with a commercial solution during 1 month contact lens daily wear on experienced lens wearers
Brien Holden Vision Institute0 个研究点目标入组 30 人开始时间: 2012年8月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Diagnosis
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent.
- •Be at least 18 years old, male or female.
- •Be experienced at wearing contact lenses.
- •Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator.
- •Have ocular health findings considered to be normal” and which would not prevent the participant from safely wearing contact lenses.
- •Correctable to at least 6/12 or better in each eye with contact lenses.
- •Be willing to not wear contact lenses for at least 2 days before each stage of the clinical trial.
排除标准
- •Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses.
- •Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.
- •Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.
- •Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant’s ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial.
- •NB: Systemic antihistamines are allowed on an as needed basis”, provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.
- •Eye surgery within 12 weeks immediately prior to enrolment for this trial.
- •Previous corneal refractive surgery.
- •Contraindications to contact lens wear.
- •Known allergy or intolerance to ingredients in any of the clinical trial products.Currently enrolled in another clinical trial.
- •Participation in a clinical trial within the previous 2 weeks for dispensing studies and 2 days between in-house studies.
- •Pregnancy* (Formal testing of pregnancy is not required. A participant’s verbal report is sufficient)
研究者
相似试验
进行中（未招募）
1 期
A prospective double-blind, randomised, cross-over trial to compare the effects of adding buprenorphine or morphine to Transtec for 'breakthrough' pain in patients with severe pain due to osteoarthritis of hip or knee. - Transtec in OA paiPatients with severe chronic pain (6 or more on a 11-point NRS) in the hips or knees due to osteoarthritis, failing on their current analgesic therapy. ICD 10: M16.50 & M17.30EUCTR2005-003230-18-GBBarts and The London NHS Trust50
撤回
1 期
A trial to evaluate the effect of Flex-Aid beverage on frequency of nocturnal foot and/or leg cramps and its safety and tolerabilityACTRN12615001245583Flex Pharma, Inc.80
已完成
不适用
A randomized, double-blind, crossover study to examine the effects of concurrent intake of alcohol and test food on cognitive function.JPRN-UMIN000035722IMEQRD Co., Ltd12
已完成
不适用
A study of two different formulations of buprenorphine in healthy volunteers.PainAddictionACTRN12617000002381iX Biopharma Pty Ltd14
进行中（未招募）
1 期
Functional MRI study of the central effects of erenumab in patients with episodic migraine.Episodic migraineMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-004875-11-ITOVARTIS FARMA S.P.A.140